Resources Repository
-
ArticlePublication 2017Estimated Economic Impact of Vaccinations in 73 LMIC, 2001-2020
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 …
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 vaccine-preventable diseases between 2001 and 2020 in 73 low- and middle-income countries largely supported by Gavi, the Vaccine Alliance. The authors used health impact models to estimate the economic impact of achieving forecasted coverages for vaccination against Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever. In…
Dynamic Transmission | Economics/Finance | Latin America & Caribbean | Sub-Saharan Africa | Infectious Diseases | Health Outcomes | State-Transition | Microsimulation | Cost-Effectiveness Analysis | Child/Nutrition | Health Systems | Health/Medicine | Middle East & North Africa | Asia & Pacific -
ReviewPublication 2016Dynamic Transmission Economic Evaluation of Infectious Disease in LMIC
Economic evaluation using dynamic transmission models is important for capturing the indirect effects of infectious …
Economic evaluation using dynamic transmission models is important for capturing the indirect effects of infectious disease interventions. The authors examine the use of these methods in low- and middle-income countries, where infectious diseases constitute a major burden. The review is comprised of two parts: (1) a summary of dynamic transmission economic evaluations across all disease areas published between 2011 and mid-2014 and (2) an in-depth review of mosquito-borne disease studies focusing on health economic methods…
Dynamic Transmission | Economics/Finance | Latin America & Caribbean | Sub-Saharan Africa | Infectious Diseases | Cost-Effectiveness Analysis | Health/Medicine | Middle East & North Africa | Asia & Pacific -
ArticlePublication 2013Estimated Mortality Impact of Vaccinations 2011–2020 in 73 GAVI Alliance Countries
From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted …
From August to December 2011, a multidisciplinary group with expertise in mathematical modeling was constituted by the GAVI Alliance and the Bill & Melinda Gates Foundation to estimate the impact of vaccination in 73 countries supported by the GAVI Alliance. The number of deaths averted in persons projected to be vaccinated during 2011–2020 was estimated for ten antigens: hepatitis B, yellow fever, Haemophilus influenzae type B (Hib), Streptococcus pneumoniae, rotavirus, Neisseria meningitidis serogroup A, Japanese…
Dynamic Transmission | Economics/Finance | Science/Technology | Latin America & Caribbean | Sub-Saharan Africa | Infectious Diseases | Health Outcomes | Mathematical Models | State-Transition | Microsimulation | Global Governance | Health/Medicine | Middle East & North Africa | Asia & Pacific -
ArticlePublication 2018Equity Impact Vaccines May Have on Averting Deaths and Medical Impoverishment
In this analysis, authors estimated the number of deaths averted and the number of cases …
In this analysis, authors estimated the number of deaths averted and the number of cases of medical impoverishment averted of ten antigens and their corresponding vaccines across income quintiles for forty-one low- and middle-income countries. The study found that vaccines administered between 2016 and 2030 would prevent 36 million deaths. Vaccines will have the greatest impact on reducing cases of poverty caused by hepatitis B, helping an estimated 14 million people avoid medical impoverishment. An…
Economics/Finance | Science/Technology | Sub-Saharan Africa | Infectious Diseases | Priority Setting/Ethics | Costing Methods | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Child/Nutrition | Global Governance | Health/Medicine | Middle East & North Africa | Asia & Pacific -
ArticlePublication 2017Revealed Willingness-to-Pay vs. Standard Cost-Effectiveness Thresholds
This study estimates the cost-effectiveness thresholds (CETs) of 16 HIV programs in South Africa. The …
This study estimates the cost-effectiveness thresholds (CETs) of 16 HIV programs in South Africa. The use of CETs based on a country’s income per capita has been criticized for not being grounded in theory or evidence, especially in low and middle-income countries (LMICs). An alternative has been produced for South Africa, based on estimates of life years saved and the country’s committed HIV budget. The authors used a previously -published optimization method to estimate CETs,…
Preferences/Values | Economics/Finance | Sub-Saharan Africa | Infectious Diseases | Priority Setting/Ethics | Cost-Effectiveness Analysis | Health/Medicine -
ArticlePublication 2017Getting it Right When Budgets are Tight: Prioritizing Responses to HIV Epidemics
Prioritizing investments across health interventions is complicated by the nonlinear relationship between intervention coverage and …
Prioritizing investments across health interventions is complicated by the nonlinear relationship between intervention coverage and epidemiological outcomes. It can be difficult for countries to know which interventions to prioritize for greatest epidemiological impact, particularly when budgets are uncertain.The authors examined four case studies of HIV epidemics in diverse settings, each with different characteristics. These case studies were based on public data available for Belarus, Peru, Togo, and Myanmar. The Optima HIV model and software package…
Economics/Finance | Latin America & Caribbean | Sub-Saharan Africa | Infectious Diseases | Priority Setting/Ethics | Costing Methods | Mathematical Models | Cost-Effectiveness Analysis | Health Systems | Health/Medicine | Middle East & North Africa | Asia & Pacific -
ArticlePublication 2017Designing an Optimal HIV Programme for South Africa
This 2017 study compares the traditional and a novel method of comparing cost-effectiveness interventions in …
This 2017 study compares the traditional and a novel method of comparing cost-effectiveness interventions in the context of HIV in South Africa, using a modeling approach. The authors argue that the assumptions of a) independence of interventions, and b) linear scale-up effects do not hold because South Africa has a large domestically funded HIV program with highly saturated coverage levels. The authors therefore aim to better allocate resources for HIV interventions in South Africa when…
Economics/Finance | Sub-Saharan Africa | Infectious Diseases | Priority Setting/Ethics | Mathematical Models | Cost-Effectiveness Analysis | Operations Research | Health Systems | Health/Medicine -
ArticlePublication 2016Funding Gap for Immunization Across 94 Low- and Middle-Income Countries
This analysis estimates immunization program costs, potentially available financing, and resulting funding gap for 94 …
This analysis estimates immunization program costs, potentially available financing, and resulting funding gap for 94 low- and middle-income countries over the five-year period of 2016–2020. Vaccine financing by country governments, GAVI, and other development sources was forecasted for vaccine, supply chain, and service delivery based on an analysis of comprehensive multi-year plans together with a series of scenarios. The authors found that that delivery of full vaccination programs across the 94 countries would result in a total…
Economics/Finance | Latin America & Caribbean | Sub-Saharan Africa | Infectious Diseases | Costing Methods | Mathematical Models | Cost-Effectiveness Analysis | Health Systems | Global Governance | Health/Medicine | Middle East & North Africa | Asia & Pacific -
ArticlePublication 2016Cost-Effectiveness of Routine Vaccination With a Live-Attenuated Dengue Vaccine: Model Comparison
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, …
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 months following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concerns about a potential increase in hospitalization risk of subsequent dengue infections, in particular among young, dengue-naïve vaccinees. This paper reports predictions from eight independent modelling groups on the long-term safety, public health impact, and cost-effectiveness of routine…
Dynamic Transmission | Economics/Finance | Latin America & Caribbean | Infectious Diseases | Mathematical Models | Cost-Effectiveness Analysis | Child/Nutrition | Health Systems | Global Governance | Climate/Environment | Health/Medicine | Asia & Pacific